BioHarvest Sciences Inc. (BHST)
Nasdaq: BHST · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 31, 2026 | Mar 31, 2025 | · |
| Revenue | 34,508 | 25,188 | 12,672 |
| Cost of revenue | 14,032 | 11,246 | 7,039 |
| Total operating expenses | 26,051 | 20,931 | 15,599 |
| Operating income | -5,575 | -6,989 | -9,966 |
| Income before income taxes | -11,059 | -12,905 | -12,564 |
| Income tax expense | -76 | -8r | 0 |
| Net income | -11,135 | -12,913 | -12,564 |
| Earnings per share, basic | -0.60 | -0.80 | -0.93 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasic